Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers

Derk Jan A. de Groot, Marjolijn N. Lub-de Hooge, Tom van Meerten, Adrienne H. Brouwers, Elisabeth G.E. de Vries

Clin Cancer Res (2024) 30 (23): 5252–5259.

https://doi.org/10.1158/1078-0432.CCR-24-1427

Published: 02 December 2024

View article titled, Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers

Journal Articles

First-in-Human Study of the Biodistribution and Pharmacokinetics of ⁸⁹Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Laura Kist de Ruijter, Jahlisa S. Hooiveld-Noeken, Danique Giesen, Marjolijn N. Lub-de Hooge, Iris C. Kok, Adrienne H. Brouwers, Sjoerd G. Elias, Margaret T.L. Nguyen, Hong Lu, Jourik A. Gietema, Mathilde Jalving, Derk J.A. de Groot, Olga Vasiljeva, Elisabeth G.E. de Vries

Clin Cancer Res (2021) 27 (19): 5325–5333.

https://doi.org/10.1158/1078-0432.CCR-21-0453

Published: 01 October 2021

View article titled, First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Includes: Supplementary data

Journal Articles

Probody Therapeutic Design of ⁸⁹Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Danique Giesen, Linda N. Broer, Marjolijn N. Lub-de Hooge, Irina Popova, Bruce Howng, Margaret Nguyen, Olga Vasiljeva, Elisabeth G.E. de Vries, Martin Pool

Clin Cancer Res (2020) 26 (15): 3999–4009.

https://doi.org/10.1158/1078-0432.CCR-19-3137

Published: 03 August 2020

View article titled, Probody Therapeutic Design of 89Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

Includes: Supplementary data

Journal Articles

⁸⁹Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Kirsten L. Moek, Stijn J.H. Waaijer, Iris C. Kok, Frans V. Suurs, Adrienne H. Brouwers, C. Willemien Menke-van der Houven van Oordt, Thijs T. Wind, Jourik A. Gietema, Carolien P. Schröder, Shekar V.K. Mahesh, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Rudolf S.N. Fehrmann, Derk Jan A. de Groot, Elisabeth G.E. de Vries

Clin Cancer Res (2019) 25 (12): 3517–3527.

https://doi.org/10.1158/1078-0432.CCR-18-2918

Published: 14 June 2019

View article titled, 89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Includes: Supplementary data

Journal Articles

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager ⁸⁹Zr-AMG211 Targeting CEA-Positive Tumors

Stijn J.H. Waaijer, Frank J. Warnders, Sabine Stienen, Matthias Friedrich, Alexander Sternjak, H. Kam Cheung, Anton G.T. Terwisscha van Scheltinga, Carolien P. Schröder, Elisabeth G.E. de Vries, Marjolijn N. Lub-de Hooge

Clin Cancer Res (2018) 24 (20): 4988–4996.

https://doi.org/10.1158/1078-0432.CCR-18-0786

Published: 15 October 2018

View article titled, Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors

Includes: Supplementary data

Journal Articles

⁸⁹Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Frederike Bensch, Laetitia E. Lamberts, Michaël M. Smeenk, Annelies Jorritsma-Smit, Marjolijn N. Lub-de Hooge, Anton G.T. Terwisscha van Scheltinga, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Marlene Thomas, Wolfgang Jacob, Keelara Abiraj, Celine Adessi, Georgina Meneses-Lorente, Ian James, Martin Weisser, Adrienne H. Brouwers, Elisabeth G.E. de Vries

Clin Cancer Res (2017) 23 (20): 6128–6137.

https://doi.org/10.1158/1078-0432.CCR-17-0311

Published: 12 October 2017

View article titled, 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Includes: Supplementary data

Journal Articles

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Clin Cancer Res (2017) 23 (11): 2730–2741.

https://doi.org/10.1158/1078-0432.CCR-16-0437

Published: 31 May 2017

View article titled, Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

Includes: Multimedia, Supplementary data

Journal Articles

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Laetitia E. Lamberts, Catharina W. Menke-van der Houven van Oordt, Eva J. ter Weele, Frederike Bensch, Michiel M. Smeenk, Johannes Voortman, Otto S. Hoekstra, Simon P. Williams, Bernard M. Fine, Daniel Maslyar, Johan R. de Jong, Jourik A. Gietema, Carolien P. Schröder, Alphons H.H. Bongaerts, Marjolijn N. Lub-de Hooge, Henk M.W. Verheul, Sandra M. Sanabria Bohorquez, Andor W.J.M. Glaudemans, Elisabeth G.E. de Vries

Clin Cancer Res (2016) 22 (7): 1642–1652.

https://doi.org/10.1158/1078-0432.CCR-15-1272

Published: 31 March 2016

View article titled, ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

Includes: Supplementary data

Journal Articles

⁸⁹Zr-trastuzumab and ⁸⁹Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Sietske B.M. Gaykema, Carolien P. Schröder, Joanna Vitfell-Rasmussen, Sue Chua, Thijs H. Oude Munnink, Adrienne H. Brouwers, Alfons H.H. Bongaerts, Mikhail Akimov, Cristina Fernandez-Ibarra, Marjolijn N. Lub-de Hooge, Elisabeth G.E. de Vries, Charles Swanton, Udai Banerji

Clin Cancer Res (2014) 20 (15): 3945–3954.

https://doi.org/10.1158/1078-0432.CCR-14-0491

Published: 31 July 2014

View article titled, 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Includes: Supplementary data

Journal Articles

Measurement of Tumor VEGF-A Levels with ⁸⁹Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

Arne R.M. van der Bilt, Anton G.T. Terwisscha van Scheltinga, Hetty Timmer-Bosscha, Carolien P. Schröder, Linda Pot, Jos G.W. Kosterink, Ate G.J. van der Zee, Marjolijn N. Lub-de Hooge, Steven de Jong, Elisabeth G.E. de Vries, Anna K.L. Reyners

Clin Cancer Res (2012) 18 (22): 6306–6314.

https://doi.org/10.1158/1078-0432.CCR-12-0406

Published: 14 November 2012

View article titled, Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

Includes: Supplementary data

Journal Articles

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

Evelien W. Duiker, Elisabeth G.E. de Vries, Devalingam Mahalingam, Gert Jan Meersma, Wytske Boersma-van Ek, Harry Hollema, Marjolijn N. Lub-de Hooge, Go M. van Dam, Robbert H. Cool, Wim J. Quax, Afshin Samali, Ate G.J. van der Zee, Steven de Jong

Clin Cancer Res (2009) 15 (6): 2048–2057.

https://doi.org/10.1158/1078-0432.CCR-08-1535

Published: 16 March 2009

View article titled, Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

Includes: Supplementary data

NARROW

Facts and Hopes for PET Imaging–Derived Immunotherapy Biomarkers

First-in-Human Study of the Biodistribution and Pharmacokinetics of ⁸⁹Zr-CX-072, a Novel Immunopet Tracer Based on an Anti–PD-L1 Probody

Probody Therapeutic Design of ⁸⁹Zr-CX-072 Promotes Accumulation in PD-L1–Expressing Tumors Compared to Normal Murine Lymphoid Tissue

⁸⁹Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake

Molecular Imaging of Radiolabeled Bispecific T-Cell Engager ⁸⁹Zr-AMG211 Targeting CEA-Positive Tumors

⁸⁹Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors

Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

⁸⁹Zr-trastuzumab and ⁸⁹Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

Measurement of Tumor VEGF-A Levels with ⁸⁹Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model

Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only